The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

计划入组 500 人 · 首次发布于 2024 年 4 月 22 日

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

计划入组 361 人 · 首次发布于 2025 年 6 月 19 日

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

计划入组 38 人 · 首次发布于 2017 年 10 月 16 日

CDK8 Target candidate (Insilico Medicine)

CDK8/19 Kinase Inhibitors therapy(senex biotechnology)

SEL120-34A free base

C₁₅H₁₈Br₂N₄

Insilico Medicine Leverages AI to Develop Novel CDK8 Inhibitor for Cancer Treatment

Senex Biotechnology Receives European Patent Allowance for CDK8/19 Inhibitor SNX631-6

FDA Lifts Partial Clinical Hold on RVU120 Trial in AML and MDS